SpeeDx Partners with Nepean Hospital to Develop Risk-Based COVID-19 Management Test
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 – a host biomarker with expression strongly correlated with disease progression in Influenza and COVID-19 patients. Test results will support life-saving decisions with rapid, risk-based information, and empower front-line medical staff to manage limited critical care facilities more effectively.
“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs.
Newly patented InSignia™ technology, that simplifies the measurement of gene expression, will underpin the creation of a simple, standardised molecular test to support risk-based management of patients with respiratory viral illness.
Read the press release